Cover Image
市場調查報告書

心臟生物標記:技術、全球市場

Cardiac Biomarkers: Technologies and Global Markets

出版商 BCC Research 商品編碼 297159
出版日期 內容資訊 英文 191 Pages
訂單完成後即時交付
價格
Back to Top
心臟生物標記:技術、全球市場 Cardiac Biomarkers: Technologies and Global Markets
出版日期: 2016年06月22日 內容資訊: 英文 191 Pages
簡介

全球心臟生物標記體外診斷檢驗市場從2014年的44億美元,到2015年到達了49億美元。預計2015-2020年的期間以年複合成長率12.4%成長,2020年達到88億美元以上。

本報告提供全球心血管疾病(CVD)生物標記市場及相關技術的調查,包含成果、估計、年複合成長率預測的世界市場趨勢,各分類的疾病分析,心臟生物標記的背景、臨床價值,專利趨勢,及政府法規等彙整資料,並將其結果為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 概要

  • 市場主要趨勢
  • 生物標記的種類
  • 心臟生物標記的至適標準
  • 生物標記的發現與核准
  • 替代市場
  • 相關市場
  • 產業內的終端用戶及利害關係者
  • 心臟疾病的流行
  • 心臟疾病的危險因素和預防
  • 心臟疾病的分類
  • 心臟病的歷史、現狀
  • 心臟生物標記診斷的未來方向性
  • 心臟生物標記的背景、臨床價值
  • 生物標記臨床指南

第4章 產業結構、競爭分析

  • 產業結構
  • 診斷法
  • 專利分析
  • 市場競爭環境
  • 政府法規
  • 價格趨勢及性價比
  • 一般的技術課題

第5章 市場摘要:各化驗

第6章 各市場:各設備

  • 臨床化學分析設備
  • 照護現場設備
  • 各設備類別市場

第7章 市場:各地區

  • 市場摘要:各地區
  • 北美市場
  • 歐洲市場
  • 亞太地區市場
  • 其他地區

第8章 企業簡介

  • ABBOTT DIAGNOSTICS
  • BG MEDICINE INC.
  • BIOMERIEUX
  • BIO-RAD LABORATORIES
  • CISBIO BIOASSAYS
  • COVANCE
  • EKF DIAGNOSTICS
  • ENZO BIOCHEM INC.
  • HOLOGIC INC.
  • MESO SCALE DIAGNOSTICS
  • ORTHO CLINICAL DIAGNOSTICS
  • PACIFIC BIOMARKERS INC.
  • PERKIN ELMER INC.
  • QIAGEN NV
  • RADIOMETER MEDICAL
  • RANDOX LABORATORIES LTD.
  • RESPONSE BIOMEDICAL CORP.
  • ROCHE HOLDING AG
  • SIGNOSIS INC.
  • SIEMENS HEALTHCARE DIAGNOSTICS
  • SINGULEX, INC.
  • THERMO FISHER SCIENTIFIC INC.
  • WUXI APPTEC
  • 潛在的參與企業

第9章 附錄

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO128B

REPORT HIGHLIGHTS

The global cardiac biomarkers market has grown to $4.9 billion in 2015 from $4.4 billion in 2014. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020.

This report provides:

  • An overview of the global market for cardiac biomarkers and related technologies.
  • Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
  • Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
  • Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
  • Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
  • Clinical guidelines and government regulations.
  • Profiles of major players in the industry.

SCOPE OF REPORT

Current and projected assay revenues during the forecast period (2015 through 2020) are presented. In addition, newly developed assays with regulatory approval and others expected to receive U.S. Food and Drug Administration approval within the forecast period are also projected. Figures for 2015 are estimated, except where actual results have been reported, because of the timing of the release of this report. For large market segments, such as cTn and natriuretic peptides, the analytical sensitivities and cutoff references for the diagnosis and prognosis values are discussed in detail. Moreover, the ongoing effort in developing a high-sensitivity troponin assay, as well as the attempt to pursue additional biomarkers for the diagnosis of congestive heart failure (CHF) and strokes are focused on in this study.

The report includes an analysis of leading and emerging competitors in the current global diagnostics market for CVDs. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed to define their specific product strategies. The competitive environment is examined, with a special focus on how instrumentation type (clinical chemistry analyzers compared with point-of-care devices) and their respective technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to enter the market during the forecast period.

Market figures are based on revenues at the manufacturers' level and are projected at 2015-U.S.-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence and diagnosis of respective diseases. Included in this report are forecasts by product, product category and by company from 2014 through 2020. The study is arranged to offer an overview of the diagnostics market accompanied by product, company and region.

Excluded from this report are nonproteomic diagnoses (i.e., molecular diagnostics), imaging technology and pharmaceutical biomarkers. Sales figures are reported in U.S. dollars, and in each case, these reflect currency fluctuations within the performance of changes in sales. Sales figures do not account for variation in local currencies. All market share data presented are on a global basis, unless specifically noted.

ANALYST'S CREDENTIALS

Anuj Pathak is a market research analyst and a management graduate in computer management. He completed his MBA, BSc from Devi Ahilya University (Indore, India). Anuj has strong knowledge and expertise in the healthcare domain, and he has worked on a variety of projects in varied domains, including healthcare and ICT. He has conducted extensive research on the pharmaceutical market, the medical device market, the biotechnology market, the surgical instrument market and other niche markets. Anuj also has experience in leading teams and training subordinates in his previous organization.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL CARDIAC BIOMARKER MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL CARDIAC BIOMARKER MARKET BY REGION, 2014-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • MAJOR TRENDS IN THE CARDIAC BIOMARKERS MARKET
    • DEVELOPMENT OF POINT-OF-CARE BIOMARKERS MARKET
    • IMPROVED CLINICAL AND ANALYTICAL SENSITIVITY
    • CHINA TO BE THE LEADING FORCE IN THE ASIAN MARKET
      • FIGURE 1: NUMBER OF PATENTS BY COUNTRY, IT* AND HEALTHCARE, 2013 (NO. OF PATENTS)
  • GLOBAL INCREASE IN LIFESTYLE-ORIENTED DISEASES AND FATALITIES
  • PATENT TRENDS
    • Cardiac Biomarkers Patent by Region
      • FIGURE 2: NUMBER OF CARDIAC BIOMARKER PATENTS BY REGION*, 2011-2015 (NO. OF PATENTS)
    • Cardiac Biomarkers by Stakeholders
      • FIGURE 3: SHARES OF STAKEHOLDERS IN CARDIAC BIOMARKERS PATENTS, 2011-2015 (NO./%)
    • Patents by Assignee
      • FIGURE 4: NUMBER OF CARDIAC BIOMARKER PATENTS BY ASSIGNEE, 2011-2015 (NO. OF PATENTS)
  • STRATEGIC TRENDS
    • FIGURE 5: TOP STRATEGIES, 2011-2015 (NUMBER)
  • TYPE OF BIOMARKERS
    • PREDICTIVE
    • DIAGNOSTIC
  • GOLD STANDARD OF CARDIAC BIOMARKERS
  • BIOMARKER DISCOVERY AND VALIDATION
    • BIOMARKER CANDIDATE SCREENING
    • BIOMARKER CANDIDATE VALIDATION
  • ALTERNATIVE MARKETS
    • DIAGNOSTIC DEVICES
    • CORONARY ANGIOGRAPHY
      • TABLE 1: PRICE RANGE OF CORONARY ANGIOGRAPHY/CT ANGIOGRAPHY ($)
  • MAGNETIC RESONANCE ANGIOGRAM
    • X-RAY IMAGING
    • ECHOCARDIOGRAPHY
      • TABLE 2: DIFFERENT BRANDS AND COST OF ECG MACHINES ($)
  • RELATED MARKETS
    • PROTEOMICS
  • END USERS AND STAKEHOLDERS IN THE BIOMARKER INDUSTRY
    • HOSPITALS AND ACADEMIA
      • TABLE 3: LEADING HOSPITALS AND INSTITUTES INVOLVED IN BIOMARKER STUDY
  • CONTRACT RESEARCH ORGANIZATIONS
    • BIOTECHNOLOGY COMPANIES
      • TABLE 4: COMPANIES INVOLVED IN BIOMARKER STUDIES
    • EPIDEMIC OF CARDIOVASCULAR DISEASE
      • TABLE 5: EPIDEMIC OF CARDIOVASCULAR DISEASES, 2015
    • RISK FACTORS AND PREVENTION OF CARDIOVASCULAR DISEASE
      • FIGURE 6: GLOBAL DISTRIBUTION OF CARDIOVASCULAR DISEASE: DALY, 2004 (PER 100,000 PEOPLE)
      • FIGURE 7: GLOBAL CARDIOVASCULAR DISEASE TRENDS, 2011-2018 (MILLION CASES)
  • CLASSIFICATION OF CARDIOVASCULAR DISEASE
    • CORONARY HEART DISEASE
      • TABLE 6: DISEASE PROFILE: CORONARY HEART DISEASE
      • TABLE 7: HEART DISEASE PERCENTAGE IN DIFFERENT RACES AND ETHNICITIES, 2013 (%)
    • ACUTE MYOCARDIAL INFARCTION
      • TABLE 8: DISEASE PROFILE: ACUTE MYOCARDIAL INFARCTION
    • HYPERTENSIVE HEART DISEASE
      • TABLE 9: DISEASE PROFILE OF HYPERTENSIVE HEART DISEASE
    • CEREBROVASCULAR DISEASE
      • TABLE 10: DISEASE PROFILE: CEREBROVASCULAR DISEASE
    • CONGESTIVE HEART FAILURE
      • TABLE 11: DISEASE PROFILE: CONGESTIVE HEART FAILURE
  • PERIPHERAL ARTERIAL DISEASE
    • OTHER DISEASES
      • TABLE 12: DISEASE PROFILE: HEMORRHAGIC STROKE
  • HISTORY AND CURRENT STATE OF HEART DISEASE
  • FUTURE DIRECTION OF CARDIAC BIOMARKERS DIAGNOSIS
  • BACKGROUND AND CLINICAL VALUE OF CARDIAC BIOMARKERS
    • BNP AND NT-PROBNP
    • C-REACTIVE PROTEIN
    • COPEPTIN
    • CREATINE KINASE MB
    • D-DIMER
    • GALECTIN-3
    • HEART FATTY ACID BINDING PROTEIN
    • MYOGLOBIN
      • TABLE 13: PRODUCT PROFILE: MYOGLOBIN
    • ST2
      • TABLE 14: BIOMARKER PROFILE: ST2
    • CARDIAC TROPONIN I/TROPONIN T
      • TABLE 15: PRODUCT PROFILE: TROPONIN
      • Description of Troponin Biomarkers
      • Troponin as the Preferred Biomarker
        • FIGURE 8: INTERPRETING ELEVATED LEVELS OF CARDIAC TROPONIN
    • CARDIAC BIOMARKERS UNDER DEVELOPMENT
      • Choline
      • Glial Fibrillary Acidic Protein
      • Ischemia-Modified Albumin
      • Myeloperoxidase
      • S100-Beta
    • CLINICAL GUIDELINES OF BIOMARKERS
      • TROPONIN/CK-MB/MYOGLOBLIN
      • BNP/NT-PROBNP
      • COPEPTIN
      • GALECTIN-3
      • C-REACTIVE PROTEIN
      • ST2

CHAPTER 4 - INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

  • INDUSTRY STRUCTURE
  • DIAGNOSTIC METHODS
    • IMMUNOASSAY
      • Radioimmunoassay
      • Enzyme-Linked Immunosorbent Assay
      • Chemiluminescent Enzyme Immunoassay
    • LIGHT SCATTERING
      • Turbidimetry
      • Nephelometry
      • Particle Counting
      • New Developments
    • LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
  • PATENT ANALYSIS
    • NEWLY ISSUED PATENTS
      • TABLE 16: PATENT TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2009-2015 (NO. OF PATENTS)
      • Patents on Assays
        • TABLE 17: PATENTS BY BIOMARKER CATEGORY, 2009-2015 (NO./%)
      • Patents by Manufacturer/Research Institute
        • TABLE 18: PATENTS BY COMPANY, 2009-2015 (NO./%)
        • TABLE 19: PATENTS ON CARDIAC BIOMARKER BY ASSIGNEE TYPE (NO./%)
        • TABLE 20: PATENT ANALYSIS BY REGION, 2009-2015 (NO./%)
        • TABLE 21: U.S. PATENT ANALYSIS, 2009-2015 (NO./%)
        • TABLE 22: EUROPEAN PATENT ANALYSIS, 2009-2015 (NO./%)
        • TABLE 23: PATENTS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2015
  • NEW PATENT APPLICATIONS
    • Patents by Focus
      • TABLE 24: PATENT APPLICATION TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, APRIL-JUNE 2015 (NO.)
      • TABLE 25: EXAMPLES OF PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015
    • Patents by Manufacturer/Research Institute
      • TABLE 26: PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015 (NO./%)
  • COMPETITIVE LANDSCAPE
    • FIGURE 9: RECENT KEY STRATEGIES OF CARDIAC BIOMARKER MARKET, 2011-2015 (NO./%)
    • TABLE 27: PARTNERSHIP AND COLLABORATION, 2011-2015
    • FIGURE 10: PARTNERSHIP AND COLLABORATION BY COMPANY,* 2011-2015 (NO./%)
  • PRODUCT APPROVALS AND PRODUCT CLEARANCES
    • TABLE 28: PRODUCT APPROVALS AND PRODUCT CLEARANCES, 2011-2015
    • FIGURE 11: PRODUCT APPROVALS AND PRODUCT CLEARANCES BY COMPANIES, 2011-2015 (NO./%)
  • NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES
    • TABLE 29: NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES, 2011-2015
    • FIGURE 12: NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES BY COMPANY, 2011-2015 (NO./%)
  • MERGERS AND ACQUISITIONS
    • TABLE 30: MERGERS AND ACQUISITIONS, 2011-2015
    • FIGURE 13: MERGERS AND ACQUISITIONS BY COMPANY, 2011-2015 (NO./%)
  • OTHER STRATEGIES
    • TABLE 31: OTHER STRATEGIES, 2011-2015
  • GOVERNMENT REGULATION
    • U.S. FDA 501K APPROVAL
      • Division Acceptance and Review
      • Examples of U.S. FDA 501(k) Approval
    • CE MARKING IN EUROPE
      • Examples of CE Marking in Europe
    • OTHER INTERNATIONAL REGULATORY AGENCIES
  • TRENDS IN PRICE AND PRICE/PERFORMANCE
  • GENERAL TECHNOLOGY ISSUES
    • SENSITIVITY AND SPECIFICITY
    • POSITIVE AND NEGATIVE PREDICTIVE VALUES
    • RECEIVER OPERATOR CHARACTERISTIC CURVES
      • FIGURE 14: RECEIVER OPERATOR CHARACTERISTIC CURVES

CHAPTER 5 - SUMMARY OF MARKET BY ASSAYS

  • TABLE 32: GLOBAL CARDIAC BIOMARKERS MARKET BY ASSAY CATEGORY, THROUGH 2020 ($ MILLIONS)

CHAPTER 6 - MARKET BY INSTRUMENT

  • CLINICAL CHEMISTRY ANALYZERS
    • FUTURE OF CLINICAL CHEMISTRY ANALYZERS
  • POINT-OF-CARE DEVICES
    • FUTURE OF POINT-OF-CARE TESTING
    • MARKET BY INSTRUMENT CATEGORY
      • TABLE 33: GLOBAL CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 34: GLOBAL CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 35: GLOBAL BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 36: GLOBAL CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 37: GLOBAL NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 38: GLOBAL OTHER BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)

CHAPTER 7 - MARKET BY REGION

  • SUMMARY OF MARKET BY REGION
  • NORTH AMERICA
    • UNITED STATES
    • CANADA
      • TABLE 39: NORTH AMERICA CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
      • TABLE 40: NORTH AMERICA CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 41: NORTH AMERICA CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 42: NORTH AMERICA BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 43: NORTH AMERICA CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 44: NORTH AMERICA NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 45: NORTH AMERICA OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
  • EUROPEAN MARKET
    • UNITED KINGDOM
    • FRANCE
    • GERMANY
      • TABLE 46: EUROPEAN CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
      • TABLE 47: EUROPEAN CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 48: EUROPEAN CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 49: EUROPEAN BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 50: EUROPEAN CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 51: EUROPEAN NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
      • TABLE 52: EUROPEAN OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
  • ASIA-PACIFIC MARKET
    • INDIA
    • CHINA
      • Regulations in China
    • JAPAN
      • Regulations in Japan
        • TABLE 53: ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
        • TABLE 54: ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
        • TABLE 55: ASIA-PACIFIC CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
        • TABLE 56: ASIA-PACIFIC BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
        • TABLE 57: ASIA-PACIFIC CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
        • TABLE 58: ASI-PACIFIC NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
        • TABLE 59: ASIA-PACIFIC MARKET FOR OTHER BIOMARKERS BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
  • MARKET IN THE REST OF THE WORLD
    • TABLE 60: REST OF WORLD CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
    • TABLE 61: REST OF WORLD CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 62: REST OF WORLD CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 63: REST OF WORLD BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 64: REST OF WORLD CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 65: REST OF WORLD NEW BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)

CHAPTER 8 - COMPANY PROFILES

  • ABBOTT DIAGNOSTICS
    • TABLE 66: ABBOTT DIAGNOSTICS: KEY PRODUCTS
    • TABLE 67: ABBOTT DIAGNOSTICS: RECENT DEVELOPMENTS
  • ALERE INC.
    • TABLE 68: ALERE INC.: KEY PRODUCTS
  • COMPANY STRATEGY
    • TABLE 69: ALERE INC.: RECENT DEVELOPMENTS
  • BECKMAN COULTER
    • TABLE 70: BECKMAN COULTER: KEY PRODUCTS
  • COMPANY STRATEGY
    • TABLE 71: BECKMAN COULTER: RECENT DEVELOPMENTS
  • BECTON, DICKINSON AND CO.
    • TABLE 72: BECTON, DICKINSON AND CO.: KEY PRODUCTS
  • COMPANY STRATEGY
    • TABLE 73: BECTON, DICKINSON AND CO.: RECENT DEVELOPMENTS
  • BG MEDICINE INC.
    • TABLE 74: BG MEDICINE INC: KEY PRODUCTS
    • TABLE 75: BG MEDICINE INC: RECENT DEVELOPMENTS
  • BIOMERIEUX
    • TABLE 76: BIOMERIEUX: KEY PRODUCTS
  • COMPANY STRATEGY
    • TABLE 77: BIOMERIEUX: RECENT DEVELOPMENTS
  • BIO-RAD LABORATORIES
    • TABLE 78: BIO-RAD LABORATORIES: KEY PRODUCTS
    • TABLE 79: BIO-RAD LABORATORIES: RECENT DEVELOPMENTS
  • CISBIO BIOASSAYS
    • TABLE 80: CISBIO BIOASSAYS: KEY PRODUCTS
  • COVANCE
    • TABLE 81: COVANCE: KEY PRODUCTS
  • EKF DIAGNOSTICS
    • TABLE 82: EKF DIAGNOSTICS: KEY PRODUCTS
    • TABLE 83: EKF DIAGNOSTICS: RECENT DEVELOPMENTS
  • ENZO BIOCHEM INC.
    • TABLE 84: ENZO BIOCHEM INC.: KEY PRODUCTS
  • HOLOGIC INC.
    • TABLE 85: HOLOGIC INC.: KEY PRODUCTS
  • MESO SCALE DIAGNOSTICS
    • TABLE 86: MESO SCALE DIAGNOSTICS: KEY PRODUCTS
  • ORTHO CLINICAL DIAGNOSTICS
    • TABLE 87: ORTHO CLINICAL DIAGNOSTICS: KEY PRODUCTS
    • TABLE 88: ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
  • PACIFIC BIOMARKERS INC.
    • TABLE 89: PACIFIC BIOMARKERS INC.: KEY PRODUCTS (CARDIOVASCULAR)
    • TABLE 90: PACIFIC BIOMARKERS INC.: RECENT DEVELOPMENTS
  • PERKIN ELMER INC.
    • TABLE 91: PERKIN ELMER INC.: KEY PRODUCTS
  • QIAGEN NV
    • TABLE 92: QIAGEN NV: KEY PRODUCTS
    • TABLE 93: QIAGEN NV: RECENT DEVELOPMENTS
  • RADIOMETER MEDICAL
    • TABLE 94: RADIOMETER MEDICAL: KEY PRODUCTS
    • TABLE 95: RADIOMETER MEDICAL: RECENT DEVELOPMENTS
  • RANDOX LABORATORIES LTD.
    • TABLE 96: RANDOX LABORATORIES LTD.: KEY PRODUCTS
    • TABLE 97: RANDOX LABORATORIES LTD.: RECENT DEVELOPMENTS
  • RESPONSE BIOMEDICAL CORP.
    • TABLE 98: RESPONSE BIOMEDICAL CORP.: KEY PRODUCTS
    • TABLE 99: RESPONSE BIOMEDICAL CORP.: RECENT DEVELOPMENTS
  • ROCHE HOLDING AG
    • TABLE 100: ROCHE HOLDING AG: KEY PRODUCTS
    • TABLE 101: ROCHE HOLDING AG: RECENT DEVELOPMENTS
  • SIGNOSIS INC.
    • TABLE 102: SIGNOSIS INC.: KEY PRODUCTS
  • SIEMENS HEALTHCARE DIAGNOSTICS
    • TABLE 103: SIEMENS HEALTHCARE DIAGNOSTICS: KEY PRODUCTS
    • TABLE 104: SIEMENS HEALTHCARE DIAGNOSTICS: RECENT DEVELOPMENTS
  • SINGULEX, INC.
    • TABLE 105: SINGULEX, INC.: KEY PRODUCTS
    • TABLE 106: SINGULEX, INC.: RECENT DEVELOPMENTS
  • THERMO FISHER SCIENTIFIC INC.
    • TABLE 107: THERMO FISHER SCIENTIFIC INC: KEY PRODUCTS
    • TABLE 108: THERMO FISHER SCIENTIFIC INC: RECENT DEVELOPMENTS
  • WUXI APPTEC
    • TABLE 109: WUXI APPTEC'S SERVICES
    • TABLE 110: WUXI APPTEC: RECENT DEVELOPMENTS
  • POTENTIAL ENTRANTS
    • EVOTEC
    • JOHNSON & JOHNSON
    • MERCK AND CO. INC.
    • QUINTILES

CHAPTER 9 - APPENDIX

  • TABLE 111: LIST OF PATENTS, 2006-2015

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL CARDIAC BIOMARKER MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: PRICE RANGE OF CORONARY ANGIOGRAPHY/CT ANGIOGRAPHY ($)
    • TABLE 2: DIFFERENT BRANDS AND COST OF ECG MACHINES ($)
    • TABLE 3: LEADING HOSPITALS AND INSTITUTES INVOLVED IN BIOMARKER STUDY
    • TABLE 4: COMPANIES INVOLVED IN BIOMARKER STUDIES
    • TABLE 5: EPIDEMIC OF CARDIOVASCULAR DISEASES, 2015
    • TABLE 6: DISEASE PROFILE: CORONARY HEART DISEASE
    • TABLE 7: HEART DISEASE PERCENTAGE IN DIFFERENT RACES AND ETHNICITIES, 2013 (%)
    • TABLE 8: DISEASE PROFILE: ACUTE MYOCARDIAL INFARCTION
    • TABLE 9: DISEASE PROFILE OF HYPERTENSIVE HEART DISEASE
    • TABLE 10: DISEASE PROFILE: CEREBROVASCULAR DISEASE
    • TABLE 11: DISEASE PROFILE: CONGESTIVE HEART FAILURE
    • TABLE 12: DISEASE PROFILE: HEMORRHAGIC STROKE
    • TABLE 13: PRODUCT PROFILE: MYOGLOBIN
    • TABLE 14: BIOMARKER PROFILE: ST2
    • TABLE 15: PRODUCT PROFILE: TROPONIN
    • TABLE 16: PATENT TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2009-2015 (NO. OF PATENTS)
    • TABLE 17: PATENTS BY BIOMARKER CATEGORY, 2009-2015 (NO./%)
    • TABLE 18: PATENTS BY COMPANY, 2009-2015 (NO./%)
    • TABLE 19: PATENTS ON CARDIAC BIOMARKER BY ASSIGNEE TYPE (NO./%)
    • TABLE 20: PATENT ANALYSIS BY REGION, 2009-2015 (NO./%)
    • TABLE 21: U.S. PATENT ANALYSIS, 2009-2015 (NO./%)
    • TABLE 22: EUROPEAN PATENT ANALYSIS, 2009-2015 (NO./%)
    • TABLE 23: PATENTS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2015
    • TABLE 24: PATENT APPLICATION TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, APRIL-JUNE 2015 (NO.)
    • TABLE 25: EXAMPLES OF PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015
    • TABLE 26: PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015 (NO./%)
    • TABLE 27: PARTNERSHIP AND COLLABORATION, 2011-2015
    • TABLE 28: PRODUCT APPROVALS AND PRODUCT CLEARANCES, 2011-2015
    • TABLE 29: NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES, 2011-2015
    • TABLE 30: MERGERS AND ACQUISITIONS, 2011-2015
    • TABLE 31: OTHER STRATEGIES, 2011-2015
    • TABLE 32: GLOBAL CARDIAC BIOMARKERS MARKET BY ASSAY CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 33: GLOBAL CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 34: GLOBAL CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 35: GLOBAL BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 36: GLOBAL CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 37: GLOBAL NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 38: GLOBAL OTHER BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 39: NORTH AMERICA CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
    • TABLE 40: NORTH AMERICA CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 41: NORTH AMERICA CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 42: NORTH AMERICA BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 43: NORTH AMERICA CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 44: NORTH AMERICA NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: NORTH AMERICA OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 46: EUROPEAN CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
    • TABLE 47: EUROPEAN CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 48: EUROPEAN CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: EUROPEAN BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 50: EUROPEAN CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 51: EUROPEAN NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 52: EUROPEAN OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 53: ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
    • TABLE 54: ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 55: ASIA-PACIFIC CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 56: ASIA-PACIFIC BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 57: ASIA-PACIFIC CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 58: ASI-PACIFIC NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 59: ASIA-PACIFIC MARKET FOR OTHER BIOMARKERS BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 60: REST OF WORLD CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
    • TABLE 61: REST OF WORLD CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 62: REST OF WORLD CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 63: REST OF WORLD BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 64: REST OF WORLD CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 65: REST OF WORLD NEW BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 66: ABBOTT DIAGNOSTICS: KEY PRODUCTS
    • TABLE 67: ABBOTT DIAGNOSTICS: RECENT DEVELOPMENTS
    • TABLE 68: ALERE INC.: KEY PRODUCTS
    • TABLE 69: ALERE INC.: RECENT DEVELOPMENTS
    • TABLE 70: BECKMAN COULTER: KEY PRODUCTS
    • TABLE 71: BECKMAN COULTER: RECENT DEVELOPMENTS
    • TABLE 72: BECTON, DICKINSON AND CO.: KEY PRODUCTS
    • TABLE 73: BECTON, DICKINSON AND CO.: RECENT DEVELOPMENTS
    • TABLE 74: BG MEDICINE INC: KEY PRODUCTS
    • TABLE 75: BG MEDICINE INC: RECENT DEVELOPMENTS
    • TABLE 76: BIOMERIEUX: KEY PRODUCTS
    • TABLE 77: BIOMERIEUX: RECENT DEVELOPMENTS
    • TABLE 78: BIO-RAD LABORATORIES: KEY PRODUCTS
    • TABLE 79: BIO-RAD LABORATORIES: RECENT DEVELOPMENTS
    • TABLE 80: CISBIO BIOASSAYS: KEY PRODUCTS
    • TABLE 81: COVANCE: KEY PRODUCTS
    • TABLE 82: EKF DIAGNOSTICS: KEY PRODUCTS
    • TABLE 83: EKF DIAGNOSTICS: RECENT DEVELOPMENTS
    • TABLE 84: ENZO BIOCHEM INC.: KEY PRODUCTS
    • TABLE 85: HOLOGIC INC.: KEY PRODUCTS
    • TABLE 86: MESO SCALE DIAGNOSTICS: KEY PRODUCTS
    • TABLE 87: ORTHO CLINICAL DIAGNOSTICS: KEY PRODUCTS
    • TABLE 88: ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
    • TABLE 89: PACIFIC BIOMARKERS INC.: KEY PRODUCTS (CARDIOVASCULAR)
    • TABLE 90: PACIFIC BIOMARKERS INC.: RECENT DEVELOPMENTS
    • TABLE 91: PERKIN ELMER INC.: KEY PRODUCTS
    • TABLE 92: QIAGEN NV: KEY PRODUCTS
    • TABLE 93: QIAGEN NV: RECENT DEVELOPMENTS
    • TABLE 94: RADIOMETER MEDICAL: KEY PRODUCTS
    • TABLE 95: RADIOMETER MEDICAL: RECENT DEVELOPMENTS
    • TABLE 96: RANDOX LABORATORIES LTD.: KEY PRODUCTS
    • TABLE 97: RANDOX LABORATORIES LTD.: RECENT DEVELOPMENTS
    • TABLE 98: RESPONSE BIOMEDICAL CORP.: KEY PRODUCTS
    • TABLE 99: RESPONSE BIOMEDICAL CORP.: RECENT DEVELOPMENTS
    • TABLE 100: ROCHE HOLDING AG: KEY PRODUCTS
    • TABLE 101: ROCHE HOLDING AG: RECENT DEVELOPMENTS
    • TABLE 102: SIGNOSIS INC.: KEY PRODUCTS
    • TABLE 103: SIEMENS HEALTHCARE DIAGNOSTICS: KEY PRODUCTS
    • TABLE 104: SIEMENS HEALTHCARE DIAGNOSTICS: RECENT DEVELOPMENTS
    • TABLE 105: SINGULEX, INC.: KEY PRODUCTS
    • TABLE 106: SINGULEX, INC.: RECENT DEVELOPMENTS
    • TABLE 107: THERMO FISHER SCIENTIFIC INC: KEY PRODUCTS
    • TABLE 108: THERMO FISHER SCIENTIFIC INC: RECENT DEVELOPMENTS
    • TABLE 109: WUXI APPTEC'S SERVICES
    • TABLE 110: WUXI APPTEC: RECENT DEVELOPMENTS
    • TABLE 111: LIST OF PATENTS, 2006-2015

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL CARDIAC BIOMARKER MARKET BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 1: NUMBER OF PATENTS BY COUNTRY, IT* AND HEALTHCARE, 2013 (NO. OF PATENTS)
    • FIGURE 2: NUMBER OF CARDIAC BIOMARKER PATENTS BY REGION*, 2011-2015 (NO. OF PATENTS)
    • FIGURE 3: SHARES OF STAKEHOLDERS IN CARDIAC BIOMARKERS PATENTS, 2011-2015 (NO./%)
    • FIGURE 4: NUMBER OF CARDIAC BIOMARKER PATENTS BY ASSIGNEE, 2011-2015 (NO. OF PATENTS)
    • FIGURE 5: TOP STRATEGIES, 2011-2015 (NUMBER)
    • FIGURE 6: GLOBAL DISTRIBUTION OF CARDIOVASCULAR DISEASE: DALY, 2004 (PER 100,000 PEOPLE)
    • FIGURE 7: GLOBAL CARDIOVASCULAR DISEASE TRENDS, 2011-2018 (MILLION CASES)
    • FIGURE 8: INTERPRETING ELEVATED LEVELS OF CARDIAC TROPONIN
    • FIGURE 9: RECENT KEY STRATEGIES OF CARDIAC BIOMARKER MARKET, 2011-2015 (NO./%)
    • FIGURE 10: PARTNERSHIP AND COLLABORATION BY COMPANY,* 2011-2015 (NO./%)
    • FIGURE 11: PRODUCT APPROVALS AND PRODUCT CLEARANCES BY COMPANIES, 2011-2015 (NO./%)
    • FIGURE 12: NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES BY COMPANY, 2011-2015 (NO./%)
    • FIGURE 13: MERGERS AND ACQUISITIONS BY COMPANY, 2011-2015 (NO./%)
    • FIGURE 14: RECEIVER OPERATOR CHARACTERISTIC CURVES
Back to Top